Medesis Pharma S.A.
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Medesis Pharma S.A. is a clinical-stage biopharmaceutical company that develops therapies for diseases with high unmet medical needs. The company's core focus is its proprietary AONYS® drug delivery platform, an innovative micro-emulsion technology. Designed for buccal (oral cavity) administration, AONYS® facilitates the intracellular delivery of diverse therapeutic molecules, such as interfering RNAs, metal ions, and peptides. A key differentiator of the platform is its ability to transport active ingredients across the blood-brain barrier, enabling new treatments for central nervous system disorders. The technology is engineered to be invisible to the immune system, allowing for protected transport. Medesis Pharma's development pipeline includes treatments for populations exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-20 12:00 |
Legal Proceedings Report
MEDESIS PHARMA : OUVERTURE D'UNE PROCÉDURE DE LIQUIDATION JUDICIAIRE
|
French | 184.2 KB | ||
| 2024-11-20 17:45 |
Earnings Release
MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’A…
|
French | 685.0 KB | ||
| 2024-11-20 17:45 |
Regulatory News Service
MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'…
|
English | 614.2 KB | ||
| 2024-11-14 18:00 |
Legal Proceedings Report
MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDIC…
|
French | 314.0 KB | ||
| 2024-11-12 18:00 |
Quarterly Report
MEDESIS PHARMA : Rapport Financier Semestriel 2024
|
French | 2.5 MB | ||
| 2024-11-12 18:00 |
Earnings Release
MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
|
French | 1.1 MB | ||
| 2024-10-08 08:00 |
Report Publication Announcement
Participation de MEDESIS PHARMA au Congrès mondial pour les études cliniques s…
|
French | 487.6 KB | ||
| 2024-10-08 08:00 |
Earnings Release
MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alz…
|
English | 461.5 KB | ||
| 2024-09-20 08:00 |
Earnings Release
MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai cliniq…
|
French | 236.8 KB | ||
| 2024-09-04 17:45 |
Pre-Annual General Meeting Information
MEDESIS PHARMA : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE G…
|
French | 274.7 KB | ||
| 2024-07-15 08:00 |
Earnings Release
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2023
|
French | 828.9 KB | ||
| 2024-07-15 08:00 |
Annual Report
MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
|
English | 737.2 KB | ||
| 2024-06-03 18:00 |
Regulatory News Service
MEDESIS PHARMA : Obtention d’un financement pour poursuivre l'analyse des résul…
|
French | 498.8 KB | ||
| 2024-03-19 18:01 |
Share Issue/Capital Change
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
|
English | 264.7 KB | ||
| 2024-03-19 18:01 |
Capital/Financing Update
Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.
|
French | 302.0 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
